Durata Therapeutics Inc  

(Public, NASDAQ:DRTX)   Watch this stock  
Find more results for DRTX
23.93
-0.07 (-0.27%)
Real-time:   11:50AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.91 - 24.04
52 week 9.15 - 24.33
Open 24.00
Vol / Avg. 144,460.00/884,631.00
Mkt cap 640.92M
P/E     -
Div/yield     -
EPS -2.46
Shares 26.78M
Beta     -
Inst. own 91%
Nov 11, 2014
Durata Therapeutics Inc at Credit Suisse Healthcare Conference Add to calendar
Nov 3, 2014
Q3 2014 Durata Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 13, 2014
Durata Therapeutics Inc at Wedbush Securities Life Sciences Conference
Aug 7, 2014
Q2 2014 Durata Therapeutics Inc Earnings Release
Aug 7, 2014
Q2 2014 Durata Therapeutics Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -88.79% -66.57%
Return on average equity -647.38% -150.73%
Employees 68 -
CDP Score - -

Address

Suite 2550, 200 South Wacker Drive
CHICAGO, IL 60606
United States - Map
+1-312-2197000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia.As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.

Officers and directors

Richard U. De Schutter Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Paul R. Edick Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Corey N. Fishman Chief Financial Officer, Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Michael W. Dunne M.D. Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
John Shannon Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Marty Carroll Director
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Director
Age: 71
Bio & Compensation  - Reuters
Wendy L. Yarno Director
Age: 59
Bio & Compensation  - Reuters
Brenton K. Ahrens Independent Director
Age: 50
Bio & Compensation  - Reuters
Lisa M. Giles Independent Director
Age: 55
Bio & Compensation  - Reuters